Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Company profile
Ticker
MNTA
Exchange
Website
CEO
Craig A. Wheeler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Momenta Pharmaceuticals Securities Corporation • Momenta Ireland Limited ...
IRS number
43561634
MNTA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
Latest ownership filings
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 192.97 mm | 192.97 mm | 192.97 mm | 192.97 mm | 192.97 mm | 192.97 mm |
Cash burn (monthly) | (no burn) | (no burn) | 19.13 mm | 21.73 mm | 13.69 mm | 19.58 mm |
Cash used (since last report) | n/a | n/a | 876.09 mm | 995.39 mm | 627.19 mm | 896.78 mm |
Cash remaining | n/a | n/a | -683.12 mm | -802.42 mm | -434.22 mm | -703.81 mm |
Runway (months of cash) | n/a | n/a | -35.7 | -36.9 | -31.7 | -35.9 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|